Floatz logo

BAY-Q-3939

Pseudomonas Infection

BayerPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pseudomonas Infection cohort.

Asset / SponsorPhaseRating
Tazobactam
Joseph L. Kuti, PharmD
Phase 4BB
CEFTOLOZANE
Joseph L. Kuti, PharmD
Phase 4BB
Aztreonam
Liverpool Heart and Chest Hospital NHS Foundation Trust
Phase 4BB
Amikacin
Insmed Incorporated
Phase 3BB
Meropenem
Joseph Kuti
Phase 4B
Ap-Pa02
Armata Pharmaceuticals, Inc.
Phase 1/2CCC
Ciprofloxacin
Bayer
Phase 1CC

Same molecule, other indications

BAY-Q-3939 is also rated in:

bronchiectasisDormant
B
Indicative ·
57 / 100
View asset →
cystic fibrosisDormant
CCC
Indicative ·
54 / 100
View asset →
Cystitis / Pyelonephritis / Cystic Fibrosis / AnthraxDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →